{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T20:03:00Z","timestamp":1793217780553,"version":"4.5.0"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"47","license":[{"start":{"date-parts":[[2024,11,22]],"date-time":"2024-11-22T00:00:00Z","timestamp":1732233600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,11,22]]},"abstract":"<jats:p>\n                    Hyperhomocysteinemia (serum homocysteine concentration\u2005&gt;\u200515 \u03bcmol\/L) is of high prevalence in chronic kidney disease (CKD). And myocardial hypertrophy is a common complication of CKD. Given that both hyperhomocysteinemia and cardiac hypertrophy have an association with CKD, we hypothesized that high level of plasma homocysteine (Hcy) is associated with a higher prevalence of ventricular hypertrophy(LVH) in adults with CKD. The registration number of the case-control study is ChiCTR2200064834. The information of inpatients with CKD including Echocardiograms and analysis of plasma Hcy concentrations were collected. We performed linear and logistic regression to investigate the association of plasma Hcy with left ventricular hypertrophy (LVH) (LVMI\u2005\u2265\u200595th percentile), adjusted for levels of hemoglobin, ferritin, cystatin C and \u03b2-adrenergic blocker therapy. Further, a stratified analysis of the relationship between plasma Hcy and LVH was carried out according to eGFR. The case records for 1068 inpatients with CKD were collected. After data soring and case-control matching, there were 374 samples screened for statistical analysis. Univariate logistic regression indicated a high level of serum Hcy had an association with LVH (OR, 1.16; 95% CI, 1.11\u20131.20). Finally, multivariable logistic regression suggested that hyperhomocysteinemia was independently associated with LVH (OR, 1.14; 95% CI, 1.10\u20131.19) after adjustment for hemoglobin, ferritin, cystatin C, and \u03b2-adrenergic receptor blocker therapy. We constructed a predicting model including the variable of Hcy for cardiac hypertrophy in CKD. The model had an area under the ROC curve (AUC) of 0.86 (95% CI: 0.82\u20130.89,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005&lt;\u2005.001). The decision curve analysis (DCA) showed a superior net clinical benefit of model with Hcy over model without Hcy. Elevated level of serum Hcy is closely associated with LVH in adults with CKD.\n                  <\/jats:p>","DOI":"10.1097\/md.0000000000040577","type":"journal-article","created":{"date-parts":[[2024,11,25]],"date-time":"2024-11-25T15:02:34Z","timestamp":1732546954000},"page":"e40577","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":6,"title":["Serum homocysteine and left ventricular hypertrophy in adults with chronic kidney disease: A case\u2013control study"],"prefix":"10.1097","volume":"103","author":[{"given":"Yanping","family":"Lei","sequence":"first","affiliation":[{"name":"Key Laboratory for Arteriosclerology of Hunan Province, Institute of Cardiovascular Disease, Hunan International Scientific and Technological Cooperation Base of Arteriosclerotic Disease, Hengyang Medical College, University of South China, Hengyang, Hunan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Cardiology, The First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, Hunan, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8362-9493","authenticated-orcid":false,"given":"Yue","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Cardiology, The First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, Hunan, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250503","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1681\/ASN.2020010081","article-title":"A land of controversy: fibroblast growth factor-23 and uremic cardiac hypertrophy.","volume":"31","author":"Bao","year":"2020","journal-title":"J Am Soc Nephrol"},{"key":"R2-20250503","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1681\/ASN.2015020200","article-title":"Loss of klotho in CKD breaks one\u2019s heart.","volume":"26","author":"Fu","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"R3-20250503","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.jacbts.2019.10.011","article-title":"Macrophage-derived exosomal Mir-155 regulating cardiomyocyte pyroptosis and hypertrophy in uremic cardiomyopathy.","volume":"5","author":"Wang","year":"2020","journal-title":"JACC Basic Transl Sci"},{"key":"R4-20250503","doi-asserted-by":"crossref","first-page":"16087","DOI":"10.1038\/s41598-018-34216-x","article-title":"Pathological cardiac remodeling occurs early in CKD mice from unilateral urinary obstruction, and is attenuated by Enalapril.","volume":"8","author":"Ham","year":"2018","journal-title":"Sci Rep"},{"key":"R5-20250503","doi-asserted-by":"crossref","first-page":"352","DOI":"10.3390\/toxins10090352","article-title":"Cardiotoxicity of uremic toxins: a driver of cardiorenal syndrome.","volume":"10","author":"Lekawanvijit","year":"2018","journal-title":"Toxins (Basel)"},{"key":"R6-20250503","doi-asserted-by":"crossref","first-page":"7698","DOI":"10.3390\/ijms21207698","article-title":"Homocysteine and mitochondria in cardiovascular and cerebrovascular systems.","volume":"21","author":"Kaplan","year":"2020","journal-title":"Int J Mol Sci"},{"key":"R7-20250503","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.bbrc.2018.11.049","article-title":"Cardioprotective effect of levosimendan against homocysteine-induced mitochondrial stress and apoptotic cell death in H9C2.","volume":"507","author":"Aminzadeh","year":"2018","journal-title":"Biochem Biophys Res Commun"},{"key":"R8-20250503","doi-asserted-by":"crossref","first-page":"4149","DOI":"10.1007\/s12325-020-01474-z","article-title":"Folic acid supplementation in patients with elevated homocysteine levels.","volume":"37","author":"Kaye","year":"2020","journal-title":"Adv Ther"},{"key":"R9-20250503","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.2215\/CJN.16191020","article-title":"Efficacy and cardiovascular safety of roxadustat for treatment of anemia in patients with non-dialysis-dependent CKD: pooled results of three randomized clinical trials.","volume":"16","author":"Provenzano","year":"2021","journal-title":"Clin J Am Soc Nephrol"},{"key":"R10-20250503","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.hfc.2020.12.002","article-title":"Anemia and management of heart failure patients.","volume":"17","author":"Beladan","year":"2021","journal-title":"Heart Fail Clin"},{"key":"R11-20250503","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1159\/000496531","article-title":"Hypoxia-inducible factor-prolyl hydroxylase domain inhibitors to treat anemia in chronic kidney disease.","volume":"198","author":"Sakashita","year":"2019","journal-title":"Contrib Nephrol"},{"key":"R12-20250503","first-page":"98","article-title":"Ferric citrate attenuates cardiac hypertrophy and fibrosis in a rat model of chronic kidney disease.","volume":"13","author":"Goto","year":"2019","journal-title":"Iran J Kidney Dis"},{"key":"R13-20250503","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.kisu.2020.12.001","article-title":"Anemia of cardiorenal syndrome.","volume":"11","author":"McCullough","year":"2021","journal-title":"Kidney Int Suppl (2011)"},{"key":"R14-20250503","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1097\/HJH.0000000000000408","article-title":"Effects of multielectrode renal denervation on cardiac and neurohumoral adaptations in resistant hypertension with cardiac hypertrophy: an EnligHTN I substudy.","volume":"33","author":"Tsioufis","year":"2015","journal-title":"J Hypertens"},{"key":"R15-20250503","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.ijcard.2016.11.115","article-title":"A prospective study on the impact of heart rate control achieved with metoprolol on cardiac performance, motor function and quality of life in Chinese chronic heart failure patients.","volume":"227","author":"Meng","year":"2017","journal-title":"Int J Cardiol"},{"key":"R16-20250503","doi-asserted-by":"crossref","first-page":"101590","DOI":"10.1016\/j.cpcardiol.2023.101590","article-title":"Left Ventricular Hypertrophy (LVH) and left ventricular geometric patterns in patients with Chronic Kidney Disease (CKD) stage 2-5 with preserved Ejection Fraction (EF): a systematic review to explore CKD stage-wise LVH patterns.","volume":"48","author":"Maqbool","year":"2023","journal-title":"Curr Probl Cardiol"},{"key":"R17-20250503","doi-asserted-by":"crossref","first-page":"843534","DOI":"10.3389\/fnut.2022.843534","article-title":"Genetic evidence supporting the causal role of homocysteine in chronic kidney disease: a Mendelian randomization study.","volume":"9","author":"Xiong","year":"2022","journal-title":"Front Nutr"},{"key":"R18-20250503","doi-asserted-by":"crossref","first-page":"113541","DOI":"10.1016\/j.expneurol.2020.113541","article-title":"Hyperhomocysteinemia is an emerging comorbidity in ischemic stroke.","volume":"336","author":"Poddar","year":"2021","journal-title":"Exp Neurol"},{"key":"R19-20250503","doi-asserted-by":"crossref","first-page":"538","DOI":"10.3389\/fnins.2016.00538","article-title":"Role of homocysteine in the ischemic stroke and development of ischemic tolerance.","volume":"10","author":"Lehotsky","year":"2016","journal-title":"Front Neurosci"},{"key":"R20-20250503","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/s41419-019-1798-4","article-title":"Homocysteine enhances neural stem cell autophagy in in vivo and in vitro model of ischemic stroke.","volume":"10","author":"Wang","year":"2019","journal-title":"Cell Death Dis"},{"key":"R21-20250503","doi-asserted-by":"crossref","first-page":"737","DOI":"10.3390\/biom11050737","article-title":"Homocysteine: biochemistry, molecular biology and role in disease.","volume":"11","author":"Hermann","year":"2021","journal-title":"Biomolecules"},{"key":"R22-20250503","first-page":"122","article-title":"Morphological and functional remodeling of the ischemic heart correlates with homocysteine levels.","volume":"10","author":"Cziraki","year":"2023","journal-title":"J Cardiovasc Dev Dis"},{"key":"R23-20250503","doi-asserted-by":"crossref","first-page":"1486157","DOI":"10.1155\/2022\/1486157","article-title":"Hyperhomocysteinemia promotes cardiac hypertrophy in hypertension.","volume":"2022","author":"Deng","year":"2022","journal-title":"Oxid Med Cell Longev"},{"key":"R24-20250503","doi-asserted-by":"crossref","first-page":"2948","DOI":"10.2174\/0929867325666180313105949","article-title":"Homocysteine and hyperhomocysteinaemia.","volume":"26","author":"Zaric","year":"2019","journal-title":"Curr Med Chem"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000040577","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T20:34:24Z","timestamp":1746304464000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000040577"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,22]]},"references-count":24,"journal-issue":{"issue":"47","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000040577","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,22]]}}}